Adebimpe Oyowe, PhD
Neurology · Braselton, GANPI 1942654181
Payments from drug & device makers
Across 232 payments — averaging $24.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$1K
- AbbVie$1K
- Pfizer$439
- UCB, Inc.$433
- Neurocrine Biosciences, Inc.$191
- Argenx US, Inc.$176
- plus $2K from 31 others
What the payments were for
- Travel & lodging$1,24722%
- Food & beverage$4,43178%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 5 | $1,460 |
| AbbVie | 86 | $1,006 |
| Pfizer | 26 | $439 |
| UCB, Inc. | 17 | $433 |
| Neurocrine Biosciences, Inc. | 7 | $191 |
| Argenx US, Inc. | 7 | $176 |
| SK Life Science, Inc. | 6 | $173 |
| Biogen | 7 | $168 |
| Lundbeck LLC | 6 | $156 |
| Eisai Inc. | 5 | $137 |
| Teva Pharmaceuticals USA, Inc. | 5 | $132 |
| Amneal Pharmaceuticals LLC | 6 | $115 |
| Lilly USA, LLC | 5 | $101 |
| Amgen | 4 | $96 |
| Kyowa Kirin, Inc. | 3 | $73 |
| Acorda Therapeutics, Inc | 4 | $72 |
| Novartis | 3 | $70 |
| Vanda Pharmaceuticals Inc. | 3 | $67 |
| Ipsen Biopharmaceuticals, Inc | 2 | $51 |
| Acadia Pharmaceuticals Inc | 2 | $47 |
| Genentech USA, Inc. | 2 | $47 |
| Neurelis, Inc. | 2 | $46 |
| Corium, LLC | 2 | $43 |
| Alnylam Pharmaceuticals Inc. | 2 | $43 |
| Grifols USA, LLC | 2 | $42 |
| Cycle Pharmaceuticals Inc | 2 | $39 |
| Merz Pharmaceuticals, LLC | 1 | $28 |
| Aucta Pharmaceuticals, Inc. | 1 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| AstraZeneca | 1 | $25 |
| Abbott | 1 | $25 |
| TG Therapeutics, Inc. | 1 | $24 |
| Boston Scientific | 1 | $23 |
| Cala Health, Inc. | 1 | $23 |
| Kedrion Biopharma, Inc. | 1 | $19 |
| MDD US Operations, LLC | 1 | $18 |
| Almatica Pharma LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$1,460
How this compares
$5,679 in reported general payments places this provider in the 65th percentile of 506 neurology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 24 | $358,582 |
| VumerityDiroximel Fumarate | 14 | $120,495 |
| UbrelvyUbrogepant | 51 | $81,231 |
| BotoxOnabotulinumtoxina | 37 | $50,265 |
| Aimovig AutoinjectorErenumab-Aooe | 57 | $43,651 |
| BriviactBrivaracetam | 11 | $29,555 |
| Nurtec OdtRimegepant Sulfate | 20 | $27,695 |
| LamictalLamotrigine | 29 | $22,929 |
| QuliptaAtogepant | 21 | $22,767 |
| KeppraLevetiracetam | 13 | $22,732 |
| Memantine Hcl | 404 | $9,827 |
| Dimethyl Fumarate | 13 | $8,820 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 254 | $8,658 |
| Primidone | 229 | $7,396 |
| Azathioprine | 37 | $7,113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Nurtec Odt | $439 | $386,27744 claims |
| AbbVieUbrelvy, Botox, Qulipta | $1,006 | $154,263109 claims |
| BiogenVumerity | $168 | $120,49514 claims |
| UCB, Inc.Briviact | $433 | $29,55511 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil | $115 | $5,93962 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 506 neurology providers in Georgia.
Other neurology in Braselton
- Jonathan LissColumbus$25M
- Marshall NashDecatur$13.6M
- James LahAtlanta$6.8M
- Jonathan GlassAtlanta$5.1M
- Sandeep VaidLawrenceville$4.2M
- Allan LeveyAtlanta$4.2M
- Ben ThrowerAtlanta$3.7M
- Jeffrey EnglishAtlanta$3.1M
- Dennis LaceyAtlanta$2.8M
- David LeschSuwanee$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.